15th Annual Psychosocial Oncology Symposium: Clinical Use of Cannabis in Cancer Care

Friday, June 14, 2019
Swedish Medical Center Cherry Hill
Education and Conference Center
500 17th Ave
Seattle, Washington


The clinical use of cannabinoids has increased significantly over the last several years, with more states throughout the country legalizing both recreational and medical utilization of cannabis.  Despite increased use, there is a lack of understanding in the medical community regarding the biological principles of cannabinoids at a systemic level, in addition to the current evidence based data on the use of cannabis for certain medical conditions.  This symposium will provide a balanced and expert overview on the clinical use of cannabinoids, issues surrounding the use of cannabis, dosages, contraindications, adverse effects, and substance use recognition.  

Through didactic lectures and interactive multidisciplinary panels, participants will be able to describe the clinical pharmacology and pharmacodynamics of cannabis and its active components, discuss potential medical uses of cannabis and cannabinoids for the treatment of various medical conditions, and assess use of cannabis as a potential therapy for individual cases in practice as supported by evidence for cannabis efficacy.

This conference is intended for all clinicians in the Northwest who treat patients facing chronic and life-threatening illness. The conference is especially relevant to clinicians in oncology, internal medicine, family medicine, psychiatry, social work, genetics, spiritual care and nursing.

View more information about the course below or select the "register online" button to register for this Swedish CME event.

*This course is sold out, walk-in registration will not be available.*

Details

The clinical use of cannabinoids has increased significantly over the last several years, with more states throughout the country legalizing both recreational and medical utilization of cannabis.  However, in a recent community cancer center poll, about one in five patients were using marijuana (2), but most had not discussed the risks vs. benefits with their provider.  With the increased use, there is need in the medical community to review the biological principles of cannabinoids at a systemic level, in addition to the current evidence based data on the use of cannabis for certain medical conditions to be able to have productive, evidence-based discussions with their patients.

When discussions about medical marijuana do occur, “78% (of oncologists) reported that these conversations were most frequently initiated by patients and their families and less than 30% felt knowledgeable enough about medical marijuana to make recommendations” (3).  Despite this, around 46% recommended it clinically (4), even though they did not feel sufficiently informed to make recommendations regarding medical marijuana.

A recent study by Ilana Bruan, MD (et. al) determined, “Although 70% of oncologists do not feel equipped to make clinical recommendations regarding medical marijuana, the vast majority conduct discussions with patients about medical marijuana and nearly one-half do, in fact, recommend it clinically. A majority believes medical marijuana is useful for certain indications. These findings are clinically important and suggest critical gaps in research, medical education, and policy regarding medical marijuana.” (3)

Health care professionals need a greater knowledge regarding the current evidence based data on the use of cannabis for certain medical conditions to address patient questions and provide appropriate assessment on the potential for use in a clinical setting. With the goal to improve patient cancer care, this symposium will provide a balanced and expert overview on the clinical use of cannabinoids, issues surrounding the use of cannabis, dosages, contraindications, adverse effects, and substance use recognition. 

Resources:

  1. Saadeh C and Rustem D. “Medical Marijuana Use in a Community Cancer Center.” Journal of Oncology Practice. September 2018. 14(9). E566-e578.
  2. “Most Oncologists Have Discussed Medical Marijuana with Patients, Survey Finds.” The ASCO Post. August 25 2018.
  3. Braun I, et al: Medical oncologists’ beliefs, practices, and knowledge regarding marijuana used therapeutically. J Clin Oncol 36:1957-1962, 2018.
  4. "Study reveals that many oncologists recommend medical marijuana clinically despite not feeling sufficiently knowledgeable to do so."  Dana-Farber Cancer Institute. News Releases. 2018 May 10.
  5. Paice JA, et al: Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 34:3325-3345, 2016.


Agenda

Objectives

At the conclusion of this symposium, the participant will provide better patient care through an increased ability to:
  • Describe the clinical pharmacology and pharmacodynamics of cannabis and its active components
  • Discuss potential medical uses of cannabis and cannabinoids for the treatment of various medical conditions
  • Assess for the use of cannabis as a potential therapy for individual cases in practice as supported by evidence for cannabis efficacy
  • Recognize the neuropsychiatric effects of cannabinoids, including misuse


The objectives listed above are overall course objectives. For lecture specific objectives, please see the course agenda.

Credit

Accreditation with Commendation
Swedish Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA Category 1 Credits

Swedish Medical Center designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Psychologists
This workshop has been approved for 6.75 CEs. The Department of Clinical Psychology at Seattle Pacific University is approved by the American Psychological Association to sponsor continuing education credit for psychologists.  The Department of Clinical Psychology at Seattle Pacific University maintains responsibility for this program and its content. At this time there is no known commercial support for this program.

For Nurses
AMA PRA Category 1 Credits™ are accepted for Washington State RN Continuing Education requirements as well as for application and renewal of specialty and advance practice certification through both ANCC and AANP (1 CNE hour is equivalent to 1 CME hour).

NASW CEUs
This workshop has been approved for 6.75 CEUs by the Washington Chapter, National Association of Social Workers (NASW) for Licensed Social Workers, Licensed Marriage & Family Therapists and Licensed Mental Health Counselors. Your Provider number is #1975-324.

Faculty

Donald I. Abrams, M.D.
Professor of Clinical Medicine
Zuckerberg San Francisco General
University of California San Francisco

Mary Brown, MA Ed
Executive Director/Lead Consultant
SMJ Consultants
AIMS Institute 

Lisa Buchanan, RN, OCN, MMC
Medical Cannabis Consultant and Educator
Dockside Cannabis

Shamim Nejad, M.D.
Medical Director
Division of Psychosocial Oncology
Swedish Cancer Institute
Swedish Medical Center

Steven Stanos, D.O.
Medical Director
Swedish Health System Pain Medicine & Services
Medical Director
Swedish Pain Services
Swedish Medical Center

Nephi Stella, Ph.D.
Professor
Department of Pharmacology and Psychiatry & Behavioral Sciences
Research Affiliate
Center on Human Development and Disability
University of Washington

Jessica Streufert, RRT
Respiratory Care Practitioner/Consultant 
SMJ Consultants
AIMS Institute

Timothy Wilens, M.D.
Chief
Division of Child and Adolescent Psychiatry
Co-Director, Center for Addiction Medicine
Massachusetts General Hospital
Professor of Psychiatry
Harvard Medical School

Swedish CME maintains full control of the content of every course we provide. It is our policy to identify and resolve all speaker and planner conflicts of interest. Each speaker is required to give a balanced, evidence-based presentation that is free of commercial bias.

Planning Committee

Shamim Nejad, M.D., Course Chair
Sandra S. Johnson, MSW, LICSW
Barbara Kollar, MHA, MCHES
Ellyn M. Lee, M.D., FACP
Sharon Mast, MSW
Raya Mawad, M.D.
Nancy Thompson, MSN, RN
Tanya Wahl, M.D.
Caye Boosalis, MEd, CME Manager
Richelle Edmonds, CME Specialist I
Danielle Posadas, CME Specialist, Sr.

Fees & Info

  Advance
Registration 
M.D./D.O.  $235*
Psychologists (APA CEs) $140*
Allied Health Professionals  $115*
Residents/Fellows/Medical Students  Please contact Swedish CME to register

*After Monday, June 3, add $30 to Advance Registration pricing

Registration Information
Pre-registration is required as space is limited. Participants who register by the "Advance Registration" date will receive a reminder email after Monday, June 3, 2019. Registrations will only be processed when accompanied by full payment. 

Cancellation
To receive a full refund, notice of cancellation must be received no later than Friday, June 7, 2019.

Special Accommodations
If you require specific dietary or physical accommodations, please contact Swedish CME at cme@swedish.org or 206-386-2755. 

Acknowledgments
This symposium may be financially supported in part by educational grants in accordance with ACCME’s Standards for Commercial Support. At the time of this printing, a complete listing of commercial supporters was not available. Appropriate acknowledgment will be given to all supporters at the time of the symposium. 

Registration Fees
Swedish CME is a self-sustaining unit and does not depend on or receive public monies in support of its educational efforts. The fees for this course include catering, all instruction materials, wi-fi access, online syllabus access and a certificate of AMA PRA Category 1 Credits™ and/or CEs.

Acknowledgements

The Planning Committee gratefully acknowledges foundation support for this conference from:

The Janet and J. Porter Reed, M.D. Fund at the Seattle Foundation.


This symposium may be financially supported in part by educational grants in accordance with ACCME’s Standards for Commercial Support. A complete listing of commercial supporters is not available at this time. Appropriate acknowledgment will be given to all supporters at the time of the symposium if this is the case.